USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/26973
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOsmola, Małgorzata
dc.date.accessioned2024-04-08T13:16:05Z
dc.date.available2024-04-08T13:16:05Z
dc.date.issued2024
dc.identifier.citationMałgorzata Osmola. Enhancing the management of hepatocellular carcinoma - oncologist perspective: [oral presentation PO 08]. In: Abordarea metabolică a patologiei hepatice: țesut adipos ca organ metabolic: curs interdisciplinar în boli digestive și metabolice, ed. a 7-a, 12-13 aprilie 2024. Chișinău, 2024, p. 27. ISBN 978-9975-82-365-4.en_US
dc.identifier.isbn978-9975-82-365-4
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/26973
dc.identifier.urihttps://online.anyflip.com/zrqpe/ugyo/mobile/index.html
dc.description.abstractMasovian Oncological Hospital, Warsaw, Poland Patients with hepatocellular carcinoma (HCC) remains a challenge in oncology, necessitating a multidisciplinary approach for effective treatment. The main challenge in patients with HCC, is not only dealing with cancer itself but also with liver cirrhosis of different origin, an underlying cause of HCC. For the successful management of HCC, integration of the Barcelona Clinic Liver Cancer (BCLC) is necessary, emphasizing its pivotal role in guiding treatment decisions and prognostication. BCLC classification stratifies HCC patients into distinct stages based on tumor burden, liver function, and performance status, thereby facilitating individualized management strategies. Earlystage HCC (BCLC 0-A) is characterized by well-preserved liver function and small, solitary tumors amenable to curative therapies such as liver resection, liver transplantation, or local ablation. Intermediate-stage disease (BCLC B) encompasses patients with multifocal tumors or vascular invasion, often managed with locoregional therapies like transarterial chemoembolization (TACE) or radioembolization. Advanced-stage HCC (BCLC C) includes patients with extensive disease or extrahepatic spread, for whom systemic therapies are recommended. Finally, end-stage HCC (BCLC D) denotes patients with decompensated liver function or performance status, warranting best supportive care. The current standard of care in the unresectable or metastatic HCC is the combination of the treatment of atezolizumab (anti- programmed death ligand 1 PD-L1) with bevacizumab (anti-vascular endothelial growth factor, VEGF), based on the result of phase 3 trial IMbrave150 study. In certain cases, multikinase inhibitors can be considered, like Sorafenib, based on the results of SHARP study, or Lenvatinib. Patients amenageable for the systemic treatment are those with Child–Pugh liver function class A, and good performance status. Patients with HCC demand a multidisciplinary approach, clinicians should integrate the BCLC classification in the management of those patients. Furthermore, the therapeutic modalities of systemic treatment in HCC are evolving and should be implemented in the management of HCC patients.en_US
dc.description.urihttps://online.anyflip.com/zrqpe/ugyo/mobile/index.html
dc.publisherMinisterul Sănătății a Republicii Moldova, USMF ”Nicolae Testemițanu”, Disciplina de gastroenterologie, Laboratorul de gastroenterologie, Asociația ”Programul educațional în boli digestive și metabolice”, Societatea de Gastroenterologie și Hepatologie din Republica Moldovaen_US
dc.titleEnhancing the management of hepatocellular carcinoma - oncologist perspectiveen_US
dc.typeOtheren_US
Appears in Collections:Curs interdisciplinar în boli digestive și metabolice: "Abordarea metabolică a patologiei hepatice: țesut adipos ca organ metabolic": ediția a 7-a, 12-13 aprilie 2024

Files in This Item:
File Description SizeFormat 
PO_08_ENHANCING_THE_MANAGEMENT_OF_HEPATOCELLULAR_CARCINOMA.pdf450.84 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback